97 results
8-K/A
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
7:18pm
to offer women diagnosed with DCIS six months of neoadjuvant endocrine therapy with the intent of determining their suitability for long-term active
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
4:00pm
diagnosed with DCIS six months of neoadjuvant endocrine therapy with the intent of determining their suitability for long-term active surveillance
8-K
EX-99.1
nynj86u
28 Jun 23
Atossa Therapeutics Announces $10M Stock Repurchase Program
9:01am
8-K
EX-99.1
rdtfj98a3ue
13 Aug 21
Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting
9:30am